May 24 (Reuters) - A panel of independent experts to the U.S. health regulator on Friday voted against the use of Novo Nordisk's weekly insulin in patients with type 1 diabetes due to risks of low blood sugar. (Reporting by Sriparna Roy and Mariam Sunny in Bengaluru; Editing by Tasim Zahid and Shailesh Kuber)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
991 DKK | +1.15% | +0.71% | +41.96% |
06-14 | Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy | RE |
06-14 | Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup | DJ |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
991 DKK | +1.15% | +0.71% | 630B | ||
205.2 PTS | -0.76% | +2.71% | - | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B | |
-4.38% | 156B | |
-3.71% | 116B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- US FDA panel votes against use of Novo Nordisk's weekly insulin in type 1 diabetes patients